Two large, landmark radiotherapy studies have shown that it is possible to treat cervical cancer effectively with high doses specifically adapted to each tumour, and with fewer serious side-effects to the surrounding normal organs.
[More]
Just over half of patients with advanced-stage esophageal cancer who are unsuitable for standard curative treatment survive for a year after receiving a combination of external beam radiotherapy and high-dose rate brachytherapy, report researchers.
[More]
At the 4th European Multidisciplinary Meeting on Urological Cancers (EMUC) held this weekend in Barcelona, Spain, specialists from radiology, urology, medical oncology and pathology said that new developments and research are already underway but benefits to patients would take some time due to the need for clinical trials, the high cost of funding research and the ability of cancer experts to efficiently take advantage of new insights and approaches, among other challenges.
[More]
Radiotherapy is a key component of cancer therapy. A majority of cancer patients get radiotherapy in some form at some point in their disease course. It can be used in a curative setting or in a palliative setting.
[More]
Scientists have identified a group of genetic markers that can predict the risk for erectile dysfunction after radiotherapy for prostate cancer.
[More]
With the goal to deliver an in-depth review of the latest multi-modal management strategies for urological cancers, the 4th European Multidisciplinary Meeting on Urological Cancers (EMUC) will be held from 16 to 18 November 2012 in Barcelona, Spain.
[More]
European cancer experts have reported their progress with promising new radiosurgical techniques for treating cancer and other conditions using new linear accelerator technology from Varian Medical Systems.
[More]
iCAD, Inc., an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, announced the first European patients have been treated with the Xoft Axxent Electronic Brachytherapy System.
[More]
Delivering radiotherapy directly to cancer of the cervix using 3-D imaging techniques is effective at controlling the return and spread of the disease and, in most cases, avoids the need for hysterectomies, according to research presented at the World Congress of Brachytherapy today.
[More]
Varian Medical Systems, Inc., the world's leading manufacturer of medical technology for treating cancer with radiotherapy, announced today it has received Shonin approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) to market the TrueBeam™ system for image-guided radiotherapy and radiosurgery in Japan.
[More]
Cancer patients in China will gain access to Varian's state-of-the-art cancer care with the announcement that a leading cancer center is acquiring a GammaMed brachytherapy afterloader from Varian Medical Systems.
[More]
It remains an unresolved issue as to whether interstitial brachytherapy has advantages compared to other therapy options in men with localized prostate cancer, nor do newer studies provide proof in this respect. This is the result of a report published by the Institute for Quality and Efficiency in Health Care (IQWiG) on 11 January 2011.
[More]
Calypso Medical Technologies, Inc., a developer of real-time localization technology used for the precise tracking of tumor targets, today announced it will showcase Dynamic Edge™ Gating Technology, recently cleared by the U.S. Food and Drug Administration, at the 52nd Annual Meeting of the American Society for Radiation Oncology (ASTRO), now underway at the San Diego Convention Center.
[More]
Varian Medical Systems has received FDA 510(k) clearance for the Acuros® XB advanced dose calculation algorithm which can complete a RapidArc® treatment plan two to three times faster than conventional planning algorithms. Varian has incorporated the Acuros algorithm for external beam radiotherapy treatment planning into its market-leading Eclipse™ treatment planning system on exhibit at the 52nd annual meeting of the American Society for Radiation Oncology (ASTRO) in San Diego October 31 - November 4.
[More]
Accuray Incorporated, a global leader in the field of radiosurgery, announced today studies underway at two leading academic institutions using CyberKnife radiosurgery in breast cancer treatment. These two studies, from the University of Texas Southwestern and Fox Chase Cancer Center, will be presented at the 52nd Annual Meeting of the American Society for Radiation Oncology (ASTRO) in San Diego from October 31 to November 4.
[More]
Varian Medical Systems is spotlighting its new TrueBeam™ medical linear accelerator for fast, powerful and efficient cancer treatments at the European Society for Therapeutic Radiology and Oncology exhibition in Barcelona next week. A fully-featured TrueBeam system will be the centerpiece of Varian's booth at the annual ESTRO meeting (Booth No. 320).
[More]
The Department of Radiation Oncology at the University of Alabama at Birmingham Comprehensive Cancer Center is among the world's first to begin using radiation technology that dramatically reduces treatment times.UAB's Hazelrig-Salter Radiation Oncology Center is the third U.S. site to acquire TrueBeam technology. TrueBeam, by Varian Medical Systems Inc., can complete a standard 40-minute radiation therapy in less than a minute for select patients. The precision of the instrument, measured in increments of less than a millimeter, comes from real-time patient imaging, positioning, beam shaping and many other data points synchronized continually as treatment progresses.
[More]
The clinical benefits of isotope-free electronic radiation therapy delivered directly to cancer sites with minimal exposure to surrounding healthy tissue continues to be substantiated by multiple publications, according to Xoft, Inc., developer of the Axxent Electronic Brachytherapy, eBx System. The leading provider of FDA-cleared Electronic Brachytherapy Systems, Xoft provides systems for single-dose intraoperative radiation therapy and accelerated brachytherapy applications.
[More]
A breakthrough external beam radiotherapy technology that is fast, precise, and has optimal dose delivery to targeted tumors while limiting damage to surrounding normal tissue, is the latest radiotherapy weapon that cancer specialists are using at Stony Brook University Medical Center to treat patients.
[More]
GE Healthcare, a unit of the General Electric Company, today will present results of a phase 1 study of anti-[18F]FACBC at the 57th annual meeting of the Society of Nuclear Medicine in Salt Lake City, Utah. The presentation closely follows the launch of the phase 2 clinical development program for anti-[18F]FACBC, which was initially discovered and developed by Emory University, Atlanta, Georgia, and was licensed to Nihon Medi-Physics Co., Ltd. (NMP) of Japan.
[More]